Login to Your Account

$45M Up Front

Allergan, Molecular Partners Sign $420M Darpin Deal

By Cormac Sheridan

Thursday, May 5, 2011
In keeping with its reputation for doing things quickly, Molecular Partners AG has secured a potential $420 million deal – a sizable $45 million of which is up front – with Allergan Inc. for its lead molecule, MP0112, within days of reporting positive Phase I/IIa data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription